CEO of Dr Reddy's Laboratories, Erez Israeli believes his company's affordable medicines benefit the U.S. market and will be ...

(Reuters) -Shares of Dr Reddy's Laboratories dropped 6% on Friday and were on track for their worst session in nearly nine ...

Dr. Reddy's Laboratories Ltd. 500124 shares slid 5.01% to 1,224.70 Indian rupees Friday, on what proved to be an all-around ...

Dr Reddy's Laboratories Ltd (RDY) reports a robust 16% YoY revenue growth, driven by strategic product launches and market ...

Dr. Reddy's Laboratories Ltd (NYSE:RDY) stock is trading lower after the company released third-quarter 2025 earnings. The pharma company clocked a net income of $165 million, marginally up from $161 ...

Dr. Reddy's Laboratories Ltd.'s profit rose 2% in the third quarter of the current financial year, but missed analysts' ...

Shares of Dr Reddy's Laboratories fell by 5% as the company's third-quarter profit rise failed to impress investors. The ...

Prabhudas Lilladher recommended reduce rating on Dr. Reddy's Laboratories with a target price of Rs 1335 in its research ...

Dr Reddy’s Laboratories on Thursday said its consolidated net profit increased 2 per cent to Rs 1,413 crore in the third ...

Dr Reddy's Laboratories reported a 2% increase in net profit to Rs 1,413 crore for the third quarter ending December 2024.

Dr Reddy’s Laboratories reports 2% increase in net profit, attributing growth to new acquisitions and product launches.

Dr. Reddy's Laboratories Ltd. 500124 shares inched down 0.54% to 1,289.35 Indian rupees Thursday, on what proved to be an all ...